Interline: correcting mutation-induced dysfunctional protein networks 

Interline has launched from Foresite Labs with $92 million in funding and six preclinical inflammatory disease and cancer programs from its platform to develop compounds that correct genetically driven dysfunction in protein networks.

Foresite Capital and Arch Venture Partners co-led Interline Therapeutics Inc.’s financing, which will also support continued platform development by the South San Francisco-based biotech...